Dr. Cindy Xiong joined Foresite Capital in 2019 as a member of the investment team, focusing on due diligence and valuing investment opportunities in private and public markets.
Cindy brings more than 12 years of scientific research and investing experiences in the healthcare industry. Prior to Foresite, Cindy earned her MBA in Healthcare Management from the Wharton school. During her time at Wharton, she interned at Lilly Asia Ventures where she analyzed biotech companies at various stages. She was a summer analyst at Tybourne Capital, a global long/short equity hedge fund, where she performed technical due diligence and financial modeling to value public and private biopharma companies and led investment decisions. Cindy received her PhD in Neurobiology from the University of Michigan, Ann Arbor. After that, she was a Helen Hay Whitney postdoctoral fellow with Dr. Wendell Lim at UCSF. She then joined Agenovir as the first scientist, where she led a team to develop CRISPR based therapeutics for HPV induced cancers. She has co-authored multiple patents and authored more than 10 research papers in top tier biomedical journals.